Phase ii trial of raltitrexed ('tomudex') in advanced small-cell lung cancer

ABSTRACT Raltitrexed, a thymidylate synthase inhibitor, was given to 21 patients with advanced small-cell lung cancer, at a dose of 3 mg m(-2) as a 15-min intravenous infusion at 21-day

intervals. All of the patients had extensive disease and 17 had received prior therapy. Patients with disease refractory to primary chemotherapy were excluded. Forty-one treatment cycles

were given (median two, range one to four). The drug was well tolerated. No objective tumour response was documented. The patients had chemoresistant disease, as shown by a response in only

one of ten patients who went on to receive alternative cytotoxic regimens. We conclude that raltitrexed given in this schedule is inactive as second line therapy for small-cell lung cancer.

Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this

journal Receive 24 print issues and online access $259.00 per year only $10.79 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now

Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer

support SIMILAR CONTENT BEING VIEWED BY OTHERS A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF SOCAZOLIMAB OR PLACEBO COMBINED WITH CARBOPLATIN AND ETOPOSIDE IN

THE FIRST-LINE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER Article Open access 13 January 2025 A RANDOMISED PHASE 2B STUDY COMPARING THE EFFICACY AND SAFETY OF BELOTECAN VS.

TOPOTECAN AS MONOTHERAPY FOR SENSITIVE-RELAPSED SMALL-CELL LUNG CANCER Article Open access 16 November 2020 A PIVOTAL BRIDGING STUDY OF LURBINECTEDIN AS SECOND-LINE THERAPY IN CHINESE

PATIENTS WITH SMALL CELL LUNG CANCER Article Open access 13 February 2024 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * CRC Department of Medical Oncology, Christie Hospital, Manchester, UK

PJ Woll Authors * PJ Woll View author publications You can also search for this author inPubMed Google Scholar * R Basser View author publications You can also search for this author

inPubMed Google Scholar * T Le Chevalier View author publications You can also search for this author inPubMed Google Scholar * P Drings View author publications You can also search for this

author inPubMed Google Scholar * G Perez Manga View author publications You can also search for this author inPubMed Google Scholar * A Adenis View author publications You can also search

for this author inPubMed Google Scholar * L Seymour View author publications You can also search for this author inPubMed Google Scholar * F Smith View author publications You can also

search for this author inPubMed Google Scholar * N Thatcher View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and

permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Woll, P., Basser, R., Le Chevalier, T. _et al._ Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer. _Br J

Cancer_ 76, 264–265 (1997). https://doi.org/10.1038/bjc.1997.373 Download citation * Issue Date: 01 July 1997 * DOI: https://doi.org/10.1038/bjc.1997.373 SHARE THIS ARTICLE Anyone you share

the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer

Nature SharedIt content-sharing initiative